The past 10 years have been very crucial for the Indian Pharma Landscape. From 2005-2015; the revenue of the top 10 companies grew at 19% which is almost at par with the industry growth of 18%. Things have significantly changed now with US markets capping prices of crucial drugs that have impacted the overall profit margins.
Indian pharma companies have to nimbly navigate contingencies by expanding the number of FDA approved sites to secure a dominant position in the US market. The US contributes about one third of the total Indian pharma exports. Furthermore, Indian pharma manufacturing companies accounted for 34 per cent of the total ANDA approvals by the US in 2016.



